Pathogenetic pathways in ovarian endometrioid adenocarcinoma: A molecular study of 29 cases

American Journal of Surgical Pathology

Volumn 33, Issue 8, 2009, Pages 1157-1163

  Geyer, Julia Turbiner ^a   López García, Maria Angeles ^d   Sánchez Estevez, Carolina ^b   Sarrió, David ^b   Moreno Bueno, Gema ^c   Franceschetti, Ilaria ^a   Palacios, José ^d   Oliva, Esther ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Centro Nacional de Investigaciones Oncológicas   (Spain)

^c INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

catenin; KRAS; Low and high grade endometrioid carcinoma; MSI; Ovary; p53; PTEN

Indexed keywords

BETA CATENIN; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER GRADING; CLINICAL ARTICLE; CODON; DNA EXTRACTION; ENDOMETRIOID CARCINOMA; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MICRODISSECTION; MICROSATELLITE INSTABILITY; NUCLEOTIDE REPEAT; OVARY ADENOCARCINOMA; PATHOGENESIS; POLYMERASE CHAIN REACTION;

ADULT; AGED; BASE SEQUENCE; CARCINOMA, ENDOMETRIOID; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 68249112910     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e3181a902e1     Document Type: Article

References (44)

1. Aure JC, Hoeg K, Kolstad P. Carcinoma of the ovary and endometriosis. Acta Obstet Gynecol Scand. 1971;50:63-67.
2. Bell DA. Origins and molecular pathology of ovarian cancer. Mod Pathol. 2005;18:S19-S32.
3. Berchuck A, Carney M. Human ovarian cancer of surface epithelium. Biochem Pharmacol. 1997;54:541-544.
4. Black D, Soslow RA, Levine DA, et al. Clinicopathologic significance of defective DNA mismatch repair in endometrial carcinoma. J Clin Oncol. 2006;24:1745-1753.
5. Brachtel EF, Sanchez-Estevez C, Moreno-Bueno G, et al. Distinct molecular alterations in complex endometrial hyperplasia (CEH) with and without immature squamous metaplasia (squamous morules). Am J Surg Path. 2005;29:1322-1329.
6. Brinton LA, Gridley G, Piersson I, et al. Cancer risk after a hospital discharge diagnosis of endometriosis. Am J Obstet Gynecol. 1997; 176:572-579.
7. Chang WY, Cheung KK, Schorge JO, et al. Bcl-2 and p53 protein expression, apoptosis and p53 mutation in human epithelial ovarian cancers. Am J Pathol. 2000;156:409-417.
8. Cuatrecasas M, Erill N, Musulen E, et al. K-ras mutations in nonmucinous ovarian epithelial tumors: a molecular analysis and clinicopathologic study of 144 patients. Cancer. 1998;82:1088-1095.
9. Dahia PL, Marsh DJ, Zheng Z, et al. Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res. 1997;57:4710-4713.
10. Dehari R, Kurman RJ, Logani S, et al. The development of highgrade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma. A morphologic and molecular genetic analysis. Am J Surg Pathol. 2007;31:1007-1012.
11. Dionigi A, Oliva E, Iafrate AJ, et al. A wide spectrum of serous carcinomas arise in ovarian serous borderline tumors: a report of 25 cases. Mod Pathol. 2007;20:S194A.
12. Faleiro-Rodrigues C, Macedo-Pinto I, Pereira D, et al. Association of e-cadherin and b-catenin immunoexpression with clinicopathologic features in primary ovarian carcinomas. Hum Pathol. 2004;35: 663-669.
13. Faleiro-Rodrigues C, Macedo-Pinto I, Pereira D, et al. Loss of b-catenin is associated with poor survival in ovarian carcinomas. Int J Gynecol Pathol. 2004;23:337-346.
14. Gamallo C, Palacios J, Moreno G, et al. b-catenin expression pattern in stage I and II ovarian carcinomas. Am J Pathol. 1999;155: 527-536.
15. Gras E, Catasus L, Arguelles R, et al. Microsatellite instability, MLH-1 promoter hypermetilation, and frameshift mutations at coding mononucleotide repeat microsatellites in ovarian tumors. Cancer. 2001;92;2829-2836.
16. Kohler MF, Kerns BJ, Humphrey PA, et al. Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. Obstet Gynecol. 1993;81:643-650.
17. Kohler MF, Marks JR, Wiseman RW, et al. Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst. 1993;85:1513-1519.
18. Kupryjanczyk J, Thor AD, Beauchamp R, et al. p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci USA. 1993;90:4961-4965.
19. Lax SF. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch. 2004;444:213-223.
20. Liu J, Albarracin CT, Chang KH, et al. Microsatellite instability and expression of hMLH1 and hMSH2 proteins in ovarian endometrioid cancer. Mod Pathol. 2004;17;75-80.
21. Martini M, Ciccarone M, Garganese G, et al. Possible involvement of hMLH1, p16 (INK4a) and PTEN in the malignant transformation of endometriosis. In J Cancer. 2002;102:398-406.
22. Mayr D, Hirschmann A, Lohrs U, et al. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. Gynecol Oncol. 2006;103;883-887.
23. Moreno-Bueno G, Gamallo C, Perez-Gallego L, et al. b-catenin expression pattern, b-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas. Diagn Mol Pathol. 2001;10:116-122.
24. Moreno-Bueno G, Hardisson D, Sanchez C, et al. Abnormalities of the APC/beta-catenin pathway in endometrial cancer. Oncogene. 2002;21:7981-7990.
25. Okamoto A, Sameshima Y, Yokoyama S, et al. Frequent allelic losses and mutations of the p53 gene in human ovarian cancer. Cancer Res. 1991;51:5171-5176.
26. Okuda T, Otsuka J, Sekizawa A, et al. p53 mutations and overexpression affect prognosis of ovarian endometrioid cancer but not clear cell cancer. Gynecol Oncol. 2003;88:318-325.
27. Oliva E, Sarrio D, Brachtel EF, et al. High frequency of b-catenin mutations in borderline endometrioid tumours of the ovary. J Pathol. 2006;208:708-713.
28. Palacios J, Gamallo C. Mutations in the b-catenin gene (CTNNB1) in endometrioid ovarian carcinomas. Cancer Res. 1998;58:1344-1347.
29. Roth LM, Emerson RE, Ulbright TM. Ovarian endometrioid tumors of low malignant potential: a clinicopathologic study of 30 cases with comparison to well-differentiated endometrioid adenocarcinoma. Am J Surg Pathol. 2003;27:1253-1259.
30. Rutgers JL, Scully RE. Ovarian mixed epithelial papillary cystadenoma of borderline malignancy of mullerian type: a clinicopathological analysis of 36 cases. Cancer. 1988;61:546-554.
31. Saegusa M, Okayasu I. Frequent nuclear b-catenin accumulation and associated mutations in endometrioid-type endometrial and ovarian carcinomas with squamous differentiation. J Pathol. 2001;194:59-67.
32. Sagae S, Kobayashi K, Nishioka Y, et al.Mutational analysis of betacatenin gene in Japanese ovarian carcinomas: frequent mutations in endometrioid carcinomas. Jpn J Cancer Res. 1999;90:510-515.
33. Sato N, Tsunoda H, Nishida M, et al. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res. 2000;60:7052-7056.
34. Shelling AN, Cooke I, Ganesan TS. The genetic analysis of ovarian cancer. Br J Cancer. 1995;72:521-527.
35. Shih IM, Kurman RJ. Ovarian tumorigenesis. A proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004;164:1511-1518.
36. Singer G, Kurman RJ, Chang HW, et al. Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol. 2002;160: 1223-1228.
37. Singer G, Oldt R III, Cohen Y, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst. 2003;95:484-486.
38. Tavassoli FA, Devilee P. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon: IARC Press; 2003;130-137;221-223.
39. Toledo G, Growdon WB, Dias-Santagata D, et al. Microsatellite instability status and clinicopathologic profile of endometrial cancer in young women (r50 years). Mod Pathol. 2008;21:S226A.
40. Wen WH, Reles A, Runnebaum IB, et al. p53 mutations and expression in ovarian cancers: correlation with overall survival. Int J Gynecol Pathol. 1999;18:29-41.
41. Willner J, Wurz K, Allison KH, et al. Alternate molecular genetic pathways in ovarian carcinomas of common histological types. Hum Pathol. 2007;38:607-613.
42. Wright K, Wilson P, Morland S, et al. Beta-catenin mutation and expression analysis in ovarian cancer: exon 3 mutations and nuclear translocation in 16% of endometrioid tumors. Int J Cancer. 1999;82: 625-629.
43. Wu R, Zhai Y, Fearon ER, et al. Diverse mechanisms of b-catenin deregulation in ovarian endometrioid adenocarcinomas. Cancer Res. 2001;61:8247-8255.
44. Wu R, Hendrix-Lucas N, Kuick R, et al. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/b-catenin and PI3K/Pten signaling pathways. Cancer Cell. 2007;11:321-333.